Yen-Dun Tony Tzeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yen-Dun Tony Tzeng has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Chia-Jung Li
Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital , Kaohsiung
5 shared publications - Chih-Chiang Hung
Division of Breast Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan
3 shared publications - Ming-Feng Hou
Division of Breast Surgery, Department of Surgery, Center for Cancer Research, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
3 shared publications - Pei-Yi Chu
Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan
3 shared publications - An-Jen Chiang
Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
2 shared publications - Hung-Yu Lin
Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan
2 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (7) , e70630
Ribociclib and Palbociclib Are Safe and Effective for Treating Metastatic Breast Cancer: A Retrospective Study
Background: Cyclin‐dependent kinase (CDK) 4/6 inhibitors are standard for treating hormone receptor‐positive metastatic breast cancer when combined with endocrine therapy. However, comparisons of first‐line treatments are scarce. Aims: In this retrospective study, we aimed to determine the effects and safety of ribociclib and palbociclib as first‐line treatments for metastatic hormone receptor‐positive breast cancer in real‐world settings at two tertiary medical centers. Methods and Results: This retrospective observational study, conducted in two tertiary medical centers, included patients receiving palbociclib or ribociclib in combination with endocrine therapy. Treatment responses were assessed by imaging studies according to RECIST 1.1 criteria. The primary endpoint was 24‐month progression‐free survival (PFS). Safety outcomes were also recorded and compared between the treatment groups. The median follow‐up times for the ribociclib and palbociclib groups were 19.7 and 24.6 months, respectively. The 24‐month PFS rates were comparable between the ribociclib and palbociclib cohorts (55.4% vs. 55.2%, respectively; hazard ratio [HR] = 1.110, 95% confidence interval [CI]: 0.605–2.035; p = 0.736), but the objective response rate was significantly higher in the palbociclib group than in the ribociclib group (43.2% vs. 30.2%, p = 0.035). A high rate of dose reduction was observed in both cohorts due to treatment‐related toxicities (41.2% in the palbociclib group vs. 47.2% in the ribociclib group). The adverse effect profiles were comparable, although the incidence of grade 1 fatigue was slightly higher in the ribociclib group than in the palbociclib group ( p = 0.043). Conclusion: In Taiwanese real‐world practice, ribociclib and palbociclib demonstrated comparable 24‐month efficacy. Our findings show that dose reductions do not compromise targeted treatment efficacy, supporting proactive toxicity‐guided dose to optimize patient tolerability without sacrificing oncological outcomes in Asian populations.
- 23 July 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (7) , e70630
Open AccessRibociclib and Palbociclib Are Safe and Effective for Treating Metastatic Breast Cancer: A Retrospective Study
Background: Cyclin‐dependent kinase (CDK) 4/6 inhibitors are standard for treating hormone receptor‐positive metastatic breast cancer when combined with endocrine therapy. However, comparisons of first‐line treatments are scarce. Aims: In this retrospective study, we aimed to determine the effects and safety of ribociclib and palbociclib as first‐line treatments for metastatic hormone receptor‐positive breast cancer in real‐world settings at two tertiary medical centers. Methods and Results: This retrospective observational study, conducted in two tertiary medical centers, included patients receiving palbociclib or ribociclib in combination with endocrine therapy. Treatment responses were assessed by imaging studies according to RECIST 1.1 criteria. The primary endpoint was 24‐month progression‐free survival (PFS). Safety outcomes were also recorded and compared between the treatment groups. The median follow‐up times for the ribociclib and palbociclib groups were 19.7 and 24.6 months, respectively. The 24‐month PFS rates were comparable between the ribociclib and palbociclib cohorts (55.4% vs. 55.2%, respectively; hazard ratio [HR] = 1.110, 95% confidence interval [CI]: 0.605–2.035; p = 0.736), but the objective response rate was significantly higher in the palbociclib group than in the ribociclib group (43.2% vs. 30.2%, p = 0.035). A high rate of dose reduction was observed in both cohorts due to treatment‐related toxicities (41.2% in the palbociclib group vs. 47.2% in the ribociclib group). The adverse effect profiles were comparable, although the incidence of grade 1 fatigue was slightly higher in the ribociclib group than in the palbociclib group ( p = 0.043). Conclusion: In Taiwanese real‐world practice, ribociclib and palbociclib demonstrated comparable 24‐month efficacy. Our findings show that dose reductions do not compromise targeted treatment efficacy, supporting proactive toxicity‐guided dose to optimize patient tolerability without sacrificing oncological outcomes in Asian populations.
- Open Access
- 2 March 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
ATP synthasome contributes to efficient energy flux in malignant breast cancer
This study investigates the metabolic alterations associated with breast cancer progression and elucidates the underlying mechanisms. Adenine nucleotide tr
- 2 March 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Open AccessATP synthasome contributes to efficient energy flux in malignant breast cancer
This study investigates the metabolic alterations associated with breast cancer progression and elucidates the underlying mechanisms. Adenine nucleotide tr
- Open Access
- 21 February 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119128
Targeting GCN5-mediated ERK lactylation: A promising drug development frontier in cancer therapy
- 21 February 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119128
Open AccessTargeting GCN5-mediated ERK lactylation: A promising drug development frontier in cancer therapy
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (3) , 221-236
2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management
Hormone receptor-positive metastatic breast cancer remains a major clinical burden and is characterized by sequential endocrine resistance over the disease course. In 2023, the Taiwan Breast Cancer Society (TBCS) published an expert consensus to support real-world decision-making in Taiwan. Subsequently, rapid advances in biomarker-informed strategies (e.g., estrogen receptor 1 and PI3K/AKT pathway alterations), endocrine partners, estrogen receptor (ER)-targeting agents (including oral selective ER degraders and emerging protein degraders), and the expanding role of antibody-drug conjugates based on human epidermal growth factor receptor 2 expression categories have materially increased the complexity of treatment selection and sequencing. Therefore, TBCS convened an expert panel to update the previous consensus while preserving its foundational framework and eight-chapter structure: risk evaluation and biomarker testing (I/II), first-line treatment selection (I/II), second-line treatment selection (I/II), and treatment options other than endocrine-based approaches (I/II). A multidisciplinary panel conducted a systematic literature review and iterative discussions using a modified Delphi process to identify the key clinical questions, update and refine statements where new evidence was practice-changing, and maintain continuity with the 2023 Consensus. The panel formulated updated recommendations, assigned levels of evidence and strengths of recommendations, and the key updates were integrated into practical treatment algorithms reflecting Taiwan's practice considerations. This updated consensus provides a continuity-based, yet evidence-responsive framework to facilitate the integration of emerging therapies into clinical practice in Taiwan and the Asia-Pacific region.
- 1 January 2026
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (3) , 221-236
Open Access2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management
Hormone receptor-positive metastatic breast cancer remains a major clinical burden and is characterized by sequential endocrine resistance over the disease course. In 2023, the Taiwan Breast Cancer Society (TBCS) published an expert consensus to support real-world decision-making in Taiwan. Subsequently, rapid advances in biomarker-informed strategies (e.g., estrogen receptor 1 and PI3K/AKT pathway alterations), endocrine partners, estrogen receptor (ER)-targeting agents (including oral selective ER degraders and emerging protein degraders), and the expanding role of antibody-drug conjugates based on human epidermal growth factor receptor 2 expression categories have materially increased the complexity of treatment selection and sequencing. Therefore, TBCS convened an expert panel to update the previous consensus while preserving its foundational framework and eight-chapter structure: risk evaluation and biomarker testing (I/II), first-line treatment selection (I/II), second-line treatment selection (I/II), and treatment options other than endocrine-based approaches (I/II). A multidisciplinary panel conducted a systematic literature review and iterative discussions using a modified Delphi process to identify the key clinical questions, update and refine statements where new evidence was practice-changing, and maintain continuity with the 2023 Consensus. The panel formulated updated recommendations, assigned levels of evidence and strengths of recommendations, and the key updates were integrated into practical treatment algorithms reflecting Taiwan's practice considerations. This updated consensus provides a continuity-based, yet evidence-responsive framework to facilitate the integration of emerging therapies into clinical practice in Taiwan and the Asia-Pacific region.
- 2 July 2023
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 26 (7) , 1220-1221
Learning from osteoporosis: TCF4 as a promising companion biomarker for breast cancer
- 2 July 2023
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 26 (7) , 1220-1221
Learning from osteoporosis: TCF4 as a promising companion biomarker for breast cancer
- Open Access
- 17 February 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (2) , 301
The Efficacy of Thrombin-Gelatin Matrix in Hemostasis for Large Breast Tumor after Vacuum-Assisted Breast Biopsy
Background: Vacuum-assisted breast biopsy (VABB) for benign breast tumor excision is a developing trend in breast surgery. The most common complication of VABB is hematoma. We assessed the efficiency of the thrombin-gelatin matrix (TGM) for hemostasis after VABB. Methods: From December 2013 to June 2017, 147 patients with breast tumors > 2 cm in size were treated with a 7-gauge ultrasound-guided EnCor EnSpire® breast biopsy system. After VABB, the TGM was applied using an iron-tube device. After injection, brief external compression for 15 min and postoperative bandage compression for approximately 12 h were applied. The medical records were reviewed and analyzed for hematoma and acute bleeding at 1 and 3 months after VABB. Results: A total of 72 patients received hemostasis via TGM, and 75 patients received hemostasis by compression. The rates of postoperative acute bleeding in the TGM group were significantly lower than those in the non-TGM group (5.5% vs. 22.7%, p = 0.003). Among patients with hematoma, there was no statistically significant difference between the two groups (25% vs. 26.7%, p = 0.85). Conclusions: This is the first cohort study to apply the TGM hemostatic matrix for post-VABB hemostasis. The TGM hemostatic matrix could be an option for patients with large breast tumors.
- 17 February 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (2) , 301
Open AccessThe Efficacy of Thrombin-Gelatin Matrix in Hemostasis for Large Breast Tumor after Vacuum-Assisted Breast Biopsy
Background: Vacuum-assisted breast biopsy (VABB) for benign breast tumor excision is a developing trend in breast surgery. The most common complication of VABB is hematoma. We assessed the efficiency of the thrombin-gelatin matrix (TGM) for hemostasis after VABB. Methods: From December 2013 to June 2017, 147 patients with breast tumors > 2 cm in size were treated with a 7-gauge ultrasound-guided EnCor EnSpire® breast biopsy system. After VABB, the TGM was applied using an iron-tube device. After injection, brief external compression for 15 min and postoperative bandage compression for approximately 12 h were applied. The medical records were reviewed and analyzed for hematoma and acute bleeding at 1 and 3 months after VABB. Results: A total of 72 patients received hemostasis via TGM, and 75 patients received hemostasis by compression. The rates of postoperative acute bleeding in the TGM group were significantly lower than those in the non-TGM group (5.5% vs. 22.7%, p = 0.003). Among patients with hematoma, there was no statistically significant difference between the two groups (25% vs. 26.7%, p = 0.85). Conclusions: This is the first cohort study to apply the TGM hemostatic matrix for post-VABB hemostasis. The TGM hemostatic matrix could be an option for patients with large breast tumors.
- Open Access
- 26 September 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (10) , 1329
Multi-Omics Reveals the Immunological Role and Prognostic Potential of Mitochondrial Ubiquitin Ligase MARCH5 in Human Breast Cancer
E3 ubiquitin-linked enzyme MARCH5, also known as membrane-associated circular finger 5, is an enzyme encoded by the human MARCH5 gene. The main objective of this study was to visualize the prognosis of MARCH5 in breast cancer and to determine the relationship between MARCH5 expression and tumor immunity. MARCH5 expression was significantly higher in several cancers, including breast cancer (BRCA), compared with corresponding normal tissues. Not only was high MARCH5 expression associated with poorer overall survival, but also MARCH5 expression was positively correlated with the number of tumor-infiltrating immune cells in BRCA malignant tissues. Furthermore, MARCH5 expression showed a strong correlation with various immune markers of BRCA, suggesting its role in regulating tumor immunity. MARCH5 is a useful prognostic biomarker in several cancers, and its expression is highly correlated with tumor immune cell infiltration, and increased MARCH5 expression may serve as a new biomarker for BRCA diagnosis and prognosis.
- 26 September 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (10) , 1329
Open AccessMulti-Omics Reveals the Immunological Role and Prognostic Potential of Mitochondrial Ubiquitin Ligase MARCH5 in Human Breast Cancer
E3 ubiquitin-linked enzyme MARCH5, also known as membrane-associated circular finger 5, is an enzyme encoded by the human MARCH5 gene. The main objective of this study was to visualize the prognosis of MARCH5 in breast cancer and to determine the relationship between MARCH5 expression and tumor immunity. MARCH5 expression was significantly higher in several cancers, including breast cancer (BRCA), compared with corresponding normal tissues. Not only was high MARCH5 expression associated with poorer overall survival, but also MARCH5 expression was positively correlated with the number of tumor-infiltrating immune cells in BRCA malignant tissues. Furthermore, MARCH5 expression showed a strong correlation with various immune markers of BRCA, suggesting its role in regulating tumor immunity. MARCH5 is a useful prognostic biomarker in several cancers, and its expression is highly correlated with tumor immune cell infiltration, and increased MARCH5 expression may serve as a new biomarker for BRCA diagnosis and prognosis.
- Open Access
Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early recurrence, high invasion, and poor prognosis. Currently, its treatment includes chemotherapy, which shows a suboptimal efficacy. However, with the increasing studies on TNBC subtypes and tumor molecular biology, great progress has been made in targeted therapy for TNBC. The new developments in the treatment of breast cancer include targeted therapy, which has the advantages of accurate positioning, high efficiency, and low toxicity, as compared to surgery, radiotherapy, and chemotherapy. Given its importance as cancer treatment, we review the latest research on the subtypes of TNBC and relevant targeted therapies.
Open AccessPathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early recurrence, high invasion, and poor prognosis. Currently, its treatment includes chemotherapy, which shows a suboptimal efficacy. However, with the increasing studies on TNBC subtypes and tumor molecular biology, great progress has been made in targeted therapy for TNBC. The new developments in the treatment of breast cancer include targeted therapy, which has the advantages of accurate positioning, high efficiency, and low toxicity, as compared to surgery, radiotherapy, and chemotherapy. Given its importance as cancer treatment, we review the latest research on the subtypes of TNBC and relevant targeted therapies.
- Open Access
- 1 January 2016
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 13 (10) , 730-740
Dehydroepiandrosterone Supplementation Combined with Whole-Body Vibration Training Affects Testosterone Level and Body Composition in Mice
Dehydroepiandrosterone (DHEA), the most abundant sex steroid, is primarily secreted by the adrenal gland and a precursor hormone used by athletes for performance enhancement. Whole-body vibration (WBV) is a well-known light-resistance exercise by automatic adaptations to rapid and repeated oscillations from a vibrating platform, which is also a simple and convenient exercise for older adults. However, the potential effects of DHEA supplementation combined with WBV training on to body composition, exercise performance, and hormone regulation are currently unclear. The objective of the study is to investigate the effects of DHEA supplementation combined with WBV training on body composition, exercise performance, and physical fatigue-related biochemical responses and testosterone content in young-adult C57BL/6 mice. In this study, male C57BL/6 mice were divided into four groups (n = 8 per group) for 6-weeks treatment: sedentary controls with vehicle (SC), DHEA supplementation (DHEA, 10.2 mg/kg), WBV training (WBV; 5.6 Hz, 2 mm, 0.13 g), and WBV training with DHEA supplementation (WBV+DHEA; WBV: 5.6 Hz, 2 mm, 0.13 g and DHEA: 10.2 mg/kg). Exercise performance was evaluated by forelimb grip strength and exhaustive swimming time, as well as changes in body composition and anti-fatigue levels of serum lactate, ammonia, glucose, creatine kinase (CK), and blood urea nitrogen (BUN) after a 15-min swimming exercise. In addition, the biochemical parameters and the testosterone content were measured at the end of the experiment. Six-week DHEA supplementation alone significantly increased mice body weight (BW), muscle weight, testosterone level, and glycogen contents (liver and muscle) when compared with SC group. DHEA supplementation alone had no negative impact on all tissue and biochemical profiles, but could not improve exercise performance. However, WBV+DHEA supplementation also significantly decreased BW, testosterone level and glycogen content of liver, as well as serum lactate and ammonia levels after the 15-min swimming exercise when compared with DHEA supplementation alone. Although DHEA supplementation alone had no beneficial effect in the exercise performance of mice, the BW, testosterone level and glycogen content significantly increased. On the other hand, WBV training combined with DHEA decreased the BW gain, testosterone level and glycogen content caused by DHEA supplementation. Therefore, WBV training could inhibit DHEA supplementation to synthesis the testosterone level or may decrease the DHEA supplement absorptive capacity in young-adult mice.
- 1 January 2016
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 13 (10) , 730-740
Open AccessDehydroepiandrosterone Supplementation Combined with Whole-Body Vibration Training Affects Testosterone Level and Body Composition in Mice
Dehydroepiandrosterone (DHEA), the most abundant sex steroid, is primarily secreted by the adrenal gland and a precursor hormone used by athletes for performance enhancement. Whole-body vibration (WBV) is a well-known light-resistance exercise by automatic adaptations to rapid and repeated oscillations from a vibrating platform, which is also a simple and convenient exercise for older adults. However, the potential effects of DHEA supplementation combined with WBV training on to body composition, exercise performance, and hormone regulation are currently unclear. The objective of the study is to investigate the effects of DHEA supplementation combined with WBV training on body composition, exercise performance, and physical fatigue-related biochemical responses and testosterone content in young-adult C57BL/6 mice. In this study, male C57BL/6 mice were divided into four groups (n = 8 per group) for 6-weeks treatment: sedentary controls with vehicle (SC), DHEA supplementation (DHEA, 10.2 mg/kg), WBV training (WBV; 5.6 Hz, 2 mm, 0.13 g), and WBV training with DHEA supplementation (WBV+DHEA; WBV: 5.6 Hz, 2 mm, 0.13 g and DHEA: 10.2 mg/kg). Exercise performance was evaluated by forelimb grip strength and exhaustive swimming time, as well as changes in body composition and anti-fatigue levels of serum lactate, ammonia, glucose, creatine kinase (CK), and blood urea nitrogen (BUN) after a 15-min swimming exercise. In addition, the biochemical parameters and the testosterone content were measured at the end of the experiment. Six-week DHEA supplementation alone significantly increased mice body weight (BW), muscle weight, testosterone level, and glycogen contents (liver and muscle) when compared with SC group. DHEA supplementation alone had no negative impact on all tissue and biochemical profiles, but could not improve exercise performance. However, WBV+DHEA supplementation also significantly decreased BW, testosterone level and glycogen content of liver, as well as serum lactate and ammonia levels after the 15-min swimming exercise when compared with DHEA supplementation alone. Although DHEA supplementation alone had no beneficial effect in the exercise performance of mice, the BW, testosterone level and glycogen content significantly increased. On the other hand, WBV training combined with DHEA decreased the BW gain, testosterone level and glycogen content caused by DHEA supplementation. Therefore, WBV training could inhibit DHEA supplementation to synthesis the testosterone level or may decrease the DHEA supplement absorptive capacity in young-adult mice.
- 1 February 2012
- Published by Elsevier in Digestive and Liver Disease
- Vol. 44 (2) , e4
Bowel obstruction with intestinal lipomatosis
- 1 February 2012
- Published by Elsevier in Digestive and Liver Disease
- Vol. 44 (2) , e4
Bowel obstruction with intestinal lipomatosis